کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5697512 1601080 2017 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Challenging the Paradigm: EGFR wild-type benefit from an EGFR inhibitor in NSCLC
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی تومور شناسی
پیش نمایش صفحه اول مقاله
Challenging the Paradigm: EGFR wild-type benefit from an EGFR inhibitor in NSCLC
چکیده انگلیسی
This article describes the case of a patient treated at a Cancer Centre in Taiwan and at the British Columbia Cancer Agency in Canada. This patient experienced a remarkable response to a number of different systemic treatments. Despite not having a detectable EGFR mutation, he had a positive and prolonged response to all three EGFR TKIs. This case challenges current treatment paradigms for the treatment of a NSCLC patient whose tumour does not have an activating EGFR mutation.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Cancer Treatment and Research Communications - Volume 11, 2017, Pages 10-16
نویسندگان
, , , , , ,